Alpha Calcitonin Gene-Related Peptide Increases Cerebral Vessel Diameter in Animal Models of Subarachnoid Hemorrhage:A Systematic Review and Meta-analysis by Flynn, Liam M C et al.
  
 
 
 
Edinburgh Research Explorer 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Alpha Calcitonin Gene-Related Peptide Increases Cerebral
Vessel Diameter in Animal Models of Subarachnoid Hemorrhage
Citation for published version:
Flynn, LMC, Begg, CJ, Macleod, MR & Andrews, PJD 2017, 'Alpha Calcitonin Gene-Related Peptide
Increases Cerebral Vessel Diameter in Animal Models of Subarachnoid Hemorrhage: A Systematic Review
and Meta-analysis' Frontiers in Neurology, vol. 8, pp. 357. DOI: 10.3389/fneur.2017.00357
Digital Object Identifier (DOI):
10.3389/fneur.2017.00357
Link:
Link to publication record in Edinburgh Research Explorer
Document Version:
Publisher's PDF, also known as Version of record
Published In:
Frontiers in Neurology
Publisher Rights Statement:
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are
credited and that the original publication in this journal is cited, in accordance with accepted academic practice.
No use, distribution or reproduction is permitted which does not comply with these terms.
General rights
Copyright for the publications made accessible via the Edinburgh Research Explorer is retained by the author(s)
and / or other copyright owners and it is a condition of accessing these publications that users recognise and
abide by the legal requirements associated with these rights.
Take down policy
The University of Edinburgh has made every reasonable effort to ensure that Edinburgh Research Explorer
content complies with UK legislation. If you believe that the public display of this file breaches copyright please
contact openaccess@ed.ac.uk providing details, and we will remove access to the work immediately and
investigate your claim.
Download date: 05. Apr. 2019
July 2017 | Volume 8 | Article 3571
Review
published: 25 July 2017
doi: 10.3389/fneur.2017.00357
Frontiers in Neurology | www.frontiersin.org
Edited by: 
Nikolaus Plesnila, 
Institute for Stroke and 
Dementia Research, Germany
Reviewed by: 
George C. Wellman, 
University of Vermont, 
United States  
W. Taylor Kimberly, 
Massachusetts General 
Hospital, United States
*Correspondence:
Liam M. C. Flynn  
lmc.flynn@gmail.com
Specialty section: 
This article was submitted 
to Stroke, 
a section of the journal 
Frontiers in Neurology
Received: 08 May 2017
Accepted: 06 July 2017
Published: 25 July 2017
Citation: 
Flynn LMC, Begg CJ, Macleod MR 
and Andrews PJD (2017) Alpha 
Calcitonin Gene-Related Peptide 
Increases Cerebral Vessel Diameter 
in Animal Models of Subarachnoid 
Hemorrhage: A Systematic Review 
and Meta-analysis. 
Front. Neurol. 8:357. 
doi: 10.3389/fneur.2017.00357
Alpha Calcitonin Gene-Related 
Peptide increases Cerebral  
vessel Diameter in Animal Models
of Subarachnoid Hemorrhage:  
A Systematic Review and Meta-
analysis
  
Liam M. C. Flynn1*, Caroline J. Begg2, Malcolm R. Macleod1 and Peter J. D. Andrews1
1 Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, United Kingdom, 2 Emergency Department, 
Edinburgh Royal Infirmary, Edinburgh, United Kingdom
Delayed cerebral ischemia (DCI) is a life-threatening complication after subarachnoid 
hemorrhage. There is a strong association between cerebral vessel narrowing and DCI. 
Alpha calcitonin gene-related peptide (αCGRP) is a potent vasodilator, which may be 
effective at reducing cerebral vessel narrowing after subarachnoid hemorrhage (SAH). 
Here, we report a meta-analysis of data from nine in vivo animal studies identified in a 
systematic review in which αCGRP was administered in SAH models. Our primary out-
come was change in cerebral vessel diameter and the secondary outcome was change 
in neurobehavioral scores. There was a 40.8 ± 8.2% increase in cerebral vessel diameter 
in those animals treated with αCGRP compared with controls (p <  0.0005, 95% CI 
23.7–57.9). Neurobehavioral scores were reported in four publications and showed a 
standardized mean difference of 1.31 in favor of αCGRP (CI −0.49 to 3.12). We conclude 
that αCGRP reduces cerebral vessel narrowing seen after SAH in animal studies but 
note that there is insufficient evidence to determine its effect on functional outcomes.
Keywords: calcitonin gene-related peptide, CGRP, cerebral vasospasm, delayed cerebral ischemia, subarachnoid 
hemorrhage
iNTRODUCTiON
Aneurysmal subarachnoid hemorrhage is a significant cause of morbidity and mortality worldwide 
with an annual incidence of 9 per 100,000 person years (1–3). 27% of all stroke-related potential years 
of life lost before the age of 65 years are attributable to subarachnoid hemorrhage (SAH), and the 
average age at first onset of SAH is 55 years (4–6). Of the 85–90% of patients who survive to reach 
hospital, up to 42% will die within 1 month of the SAH and 20% remain dependent on others for 
activities of daily living (6, 7).
Despite successful treatment of the ruptured aneurysm and reduction of the risk of rebleeding, 
approximately 30% of treated patients develop focal neurological or cognitive deficits conventionally 
attributed to delayed cerebral ischemia (DCI) (8–11). A strong association exists between cerebral 
vessel narrowing and DCI, and it has been suggested that treating vessel narrowing after SAH may 
improve outcomes (12).
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Alpha calcitonin gene-related peptide (αCGRP) is an endog-
enous neuropeptide and powerful vasodilator. αCGRP exerts 
its relaxing properties through nitric oxide and endothelium-
dependent or endothelin-independent pathways (13). Endoge-
nous αCGRP appears to be released and subsequently depleted 
in response to cerebral vasoconstriction after SAH, leading to the 
suggestion that exogenous αCGRP may be beneficial in manag-
ing DCI (14–16). Several animal studies and three human trials 
have investigated the effect of αCGRP on cerebral arteries after 
SAH with a view to administering αCGRP as a treatment for 
DCI (17–40). However, there has been no systematic summary 
assessing the efficacy of αCGRP in reducing cerebral vasospasm 
in animal models.
Here, we use this approach to summarize data from publica-
tions reporting in vivo animal studies that investigated the effects 
of αCGRP after experimental SAH.
MeTHODS
The study protocol has been published elsewhere and is avail-
able open access but a brief description is given below (41).
Search Strategy and Study Selection
In January 2015, we searched two electronic databases (MEDLINE 
via PubMed Central, and EMBASE via OvidSP) using the key 
words “alpha calcitonin gene-related peptide,” “αCGRP,” and 
“subarachnoid hemorrhage” in combination using the Boolean 
operator [AND]. The search was restricted to “other animals.” Two 
investigators (Liam M. C. Flynn and Caroline J. Begg) indepen-
dently screened the abstracts and titles to identify those that met 
our inclusion criteria. Any differences were resolved by discussion 
with a third reviewer (Peter J. D. Andrews). We included in vivo 
animal studies describing the effect of αCGRP in animal models 
of SAH where outcome was reported as a change in arterial diam-
eter and the articles were published in English. We also included 
studies which examined in vivo SAH and αCGRP administration 
with postmortem in vitro measurements of artery diameter.
The above search was repeated in July 2017 using the same 
methods. No further studies meeting eligibility criteria were 
identified.
Data extraction
Two investigators independently extracted data relating to 
species of animal and weight; method of inducing SAH (single 
injection, double injection, or clot placement); whether the 
basilar artery, middle cerebral artery, anterior cerebral artery, 
or internal carotid artery were measured; the method of meas-
urement (angiography, in  vitro measurement or direct in  vivo 
visualization); anesthetic agent used; dose of αCGRP and time of 
administration from SAH; reporting and method of randomiza-
tion; reporting and method of blinding; animal welfare guideline 
statement; statement of sample size calculation; whether there 
was a statement of potential conflicts of interest and the use of 
animals with comorbidities. Study quality was assessed using 
the CAMARADES 10-item quality checklist (42). One point was 
awarded for each of (1) publication in a peer-reviewed journal, 
(2) statement of control temperature, (3) randomized intervention 
allocation, (4) intervention allocation concealment, (5) blinded 
assessment of outcome, (6) avoidance of anesthetics with marked 
intrinsic neuroprotective properties (ketamine), (7) statement of 
a priori sample size collection, (8) statement of compliance with 
regulatory requirements, (9) conflicts of interest statement, and 
(10) use of animals with comorbidities.
For meta-analysis, we recorded arterial diameter for inter-
vention and control groups as a percentage from baseline (mean 
values and a measure of variance with the number of animals per 
group). Where a single control group was used for multiple treat-
ment groups, we adjusted the size of the control group entered 
into the meta-analysis by dividing the size of the control group 
by the number of treatment groups served (43).
Two of the nine publications did not report quantitative 
data in their text, only presenting graphed data (26, 32). Mean 
values with SEM were estimated from the graphs of these studies 
using Universal Desktop Ruler for Windows.
Statistical Analysis
We performed meta-analysis using normalized mean difference 
with a random effects model (43). We used univariate meta-
regression to explore associations of animal species, sex, strain, 
and quality issues. We used meta-regression of transformed data 
using a three-component cubic spline to assess dose–response. 
Where multiple experiments were performed in the same 
publication we treated these as separate studies (43). All in vivo 
experiments investigating the effect of αCGRP in animal models 
of SAH where outcome was reported as a change in arterial 
diameter were included. We also included experiments which 
examined in  vivo SAH and αCGRP administration with post-
mortem in vitro measurements of artery diameter. Where one 
study administered different doses of αCGRP to separate groups 
of animals but had a shared control group we treated these 
as separate experiments and divided the number of controls 
between the experiments as per Vesterinen et al. (43). Results are 
presented as the mean ± SE unless otherwise stated. Statistical 
analysis was performed with STATA 14 (StataCorp LP).
ReSULTS
We identified 142 publications from our initial search. After 
combining MEDLINE and EMBASE results and deleting dupli-
cates, 57 publications remained. Titles and abstracts were then 
screened for eligibility by two authors resulting in 21 publications 
investigating αCGRP and cerebral vessel narrowing (17–37). 
After examining the full papers of these abstracts and removing 
those with in  vitro αCGRP administration (n =  12) and those 
which lacked SAH models, nine eligible publications remained 
(17, 21, 22, 26, 27, 32, 35–37). The nine publications included in 
the review were published between 1989 and 2013 (median year 
1996). From the 9 publications, 20 experiments were included in 
meta-analysis (Figure 1).
Characteristics of Studies
The total number of animals included in analysis was 251, 
and the median number of animals used per experiment was 
9 [interquartile range (IQR) 6–14]. Twelve experiments used 
FiGURe 1 | Flowchart of study selection. SAH, subarachnoid hemorrhage; αCGRP, alpha calcitonin gene-related peptide.
TABLe 1 | Study characteristics.
Publications, no. 9
Experiments, no. 20
Animals, no. 251
Median number of animals per experiment, median (IQR) 9 (6–14)
Species, no. (%) of experiments
Rabbit 12 (60)
Dog 5 (25)
Rat 2 (10)
Monkey 1 (5)
SAH induction, no. (%) of experiments
Autologous single injection method 12 (60)
Autologous double injection method 7 (35)
Autologous blood clot placement 1 (5)
Vessel examined
Basilar artery 19 (95)
MCA, ICA, and ACA 1 (5)
Method of visualizing vessel diameter
Angiography 16 (80)
In vitro sections 3 (15)
Direct in vivo visualization 1 (5)
Preparation of αCGRP
CGRP in solution 13 (65)
Gene transfer 4 (20)
Slow-release tablet 3 (15)
Timing of αCGRP administration
Before SAH 3 (15)
<1 day after SAH 1 (5)
1–3 days after SAH 16 (80)
Time of outcome assessment after administration of CGRP
<1 h 4 (20)
1–3 days 12 (60)
5–7 days 4 (20)
Study quality [median (IQR)] 4 (2–6)
IQR, interquartile range; SAH, subarachnoid hemorrhage; αCGRP, alpha calcitonin 
gene-related peptide; MCA, middle cerebral artery; ACA, anterior cerebral artery; ICA, 
internal carotid artery.
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rabbits (n = 156, 62% of all animals). Four experiments used New 
Zealand White, and eight experiments used Japanese White. Five 
experiments used mongrel dogs (n =  45, 18% of all animals). 
Two experiments used rats (n =  40, 16% of all animals). One 
used Wistar rats, and the other used Sprague Dawley rats. The 
remaining experiment used Macaca fascicularis (n = 10, 4% of 
all animals). The median number of study quality checklist items 
scored was 4 (IQR 2–6). No studies used animals with comor-
bidities; reported a statement of potential conflicts of interest or 
stated an a priori sample size calculation. 40% of studies reported 
control of body temperature. 20% described a randomized treat-
ment allocation, and 45% reported allocation concealment. Half 
of the experiments used a blinded assessment of outcome, and 
half used an anesthetic agent other than ketamine. All studies 
were published in peer-reviewed journals, and 70% reported 
compliance with local animal welfare guidelines. In 16/20 (80%) 
of the experiments, SAH was induced by autologous blood injec-
tion by either single or double injection methods, the remainder 
were induced with blood clot placement. Further study charac-
teristics are presented in Tables 1 and 2.
Treatment effect
All 21 publications reporting in vivo and in vitro experiments 
demonstrated a dilation of cerebral arteries after αCGRP 
administration. Of the 20 eligible in  vivo experiments (taken 
from the nine eligible publications) included in meta-analysis, 
there was a 40.8 ± 8.2% increase in cerebral vessel diameter in 
the αCGRP group compared with controls (p < 0.0005, 95% CI 
23.7–57.9, I2 96%, Figure 2). There was also a significant dose–
response to αCGRP in the 10 experiments, which administered 
a single dose into the cerebroventricular system (Figure 3).
FiGURe 3 | Dose–response relationship. 10−12 mol/kg of alpha calcitonin 
gene-related peptide (αCGRP), 3.1 ± 14.2%. 10−11 mol/kg αCGRP, 
32 ± 7.8%. 10−10 mol/kg αCGRP, 67 ± 9.7%. The error bars represent SE 
while the shaded gray area represents the SE of the grouped (all experiments 
with single doses) estimate. Differences were statistically significant (p < 0.05).
FiGURe 2 | Comparison of individual experiments ranked according to the 
effect of alpha calcitonin gene-related peptide on change in cerebral vessel 
diameter. Vertical error bars represent 95% confidence intervals for the 
individual estimates while the gray area represents the 95% interval for  
the grouped (all studies) estimate. Percentage change is in comparison  
to post-subarachnoid hemorrhage diameter or control values, depending  
upon how the original publication reported results.
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The effect size tended to be lower in studies that reported 
randomization, blinded assessment of outcome, blinded induc-
tion of SAH, and use of an anesthetic agent without intrinsic 
neuroprotective properties. However, none of these observations 
reached statistical significance. There was also a trend toward 
lower effect size in studies reporting compliance with more 
quality checklist items. This ranged from 57.3 ± 10.7% (p < 0.05) 
from experiments with a quality score (QS) of 1 to 28.1 ± 9.1% 
(p < 0.01) from experiments with a QS of 6 (see Figure 4). There 
was no statistically significant difference in treatment effect 
between species.
FiGURe 4 | Relationship between quality score of studies and estimated 
efficacy of alpha calcitonin gene-related peptide at dilating cerebral arteries. 
See Section “Methods” for quality scoring criteria. Error bars represent SE 
while the gray area represents the grouped (all studies) estimate. Differences 
were not statistically significant (p > 0.05).
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Neurological Outcome and Adverse 
effects
Four studies reported an effect on neurological outcome after 
αCGRP administration (17, 21, 22, 35). The standardized mean 
difference was 1.31 (95% CI −0.49 to 3.12, Q 40.5, n = 65 animals) 
in favor of αCGRP. Tian et  al. reported neurological outcome 
based on a comprehensive scoring system (0–48, 0 = best score, 
48 =  worst score) measured three times daily and based upon 
the assessment of four functions, which has been used elsewhere 
(35, 44). The mean neurological outcome on day 7 for the 
αCGRP group was significantly better than for the control group 
(10.67 ± 1.16 versus 22.33 ± 2.08, respectively, p < 0.001). Imaizumi 
et al. assessed neurological outcome based on food intake and a 
slope tolerance test on days 2, 3, and 4 post-SAH (21). No significant 
difference was found between the αCGRP and control groups for 
either assessment. Inoue et al. reported no significant difference in 
food intake, observable hemiparesis, consciousness disturbance or 
response to stimulation between the αCGRP and control groups 
(22). Ahmad et al. reported neurological outcome from grade I 
(normal) to grade III (unable to stand and presented abnormal 
posture) in addition to performing a slope tolerance test. Two 
rabbits in the control group were grade II (slow in response but 
able to walk) and III, respectively, all other rabbits were normal, 
and there was no statistical difference between the groups in the 
slope tolerance test. In all studies where it was measured, food 
intake was decreased after SAH, but there was no significant dif-
ference between the αCGRP and control groups. Inoue et al. noted 
a significant decrease in weight in their αCGRP group compared 
with the control group at day 14, but note no other adverse effects 
and were unable to explain this change in weight.
Eight publications reported physiological parameters that 
might be associated with adverse events. There was no significant 
difference in systemic arterial pressures or arterial blood gas 
results between the aCGRP or control groups. Imaizumi et  al. 
found that all animals tended to have an increased respiratory rate 
for approximately 6 h after intrathecal injection of either αCGRP 
or vehicle and demonstrated a high blood pH and low pCO2, but 
again no difference between the groups (21). Both Nozaki et al. 
(16) and Toshima et al. (36) demonstrated a decrease in mean 
arterial blood pressure when αCGRP was administered intrave-
nously, which was not seen by intrathecal administration. The 
study by Toshima et al. demonstrates a marked decrease in mean 
arterial blood pressure following intravenous administration 
of αCGRP which is not seen with intracisternal administration 
(~70 versus ~40 mmHg at 30 min after αCGRP administration).
DiSCUSSiON
Intrathecal administration of αCGRP dilates cerebral arteries in 
a dose-dependent manner in animal models and appears to be 
associated with fewer systemic effects than intravenous admin-
istration, chiefly the avoidance of hypotension. Furthermore, 
the effect of αCGRP on cerebral arteries appears to be more 
pronounced in the context of SAH, possibly because sensitivity 
of the artery to αCGRP may be greater owing to the depletion 
of endogenous αCGRP after SAH (30, 45). Alternatively, it may 
be that these arteries have a higher capacity for dilation after 
being constricted following SAH. In addition to the decreased 
systemic side effects seen by intrathecal administration, this route 
exposes αCGRP to the abluminal side of the blood vessel wall 
in a way more akin to its endogenous action. αCGRP is able to 
dilate cerebral arteries independently of endothelial cells, which 
are morphologically damaged after SAH and so avoids a problem 
associated with endothelin antagonists (46, 47).
Other effects of αCGRP were also reported. Sun et al. observed 
a reduction in cortical cell death, decreased endothelial death 
and upregulated vascular endothelial growth factor with evidence 
of angiogenesis after αCGRP administration (32).
There is robust evidence that αCGRP dilates cerebral blood 
vessels after SAH in animal models, and there is a clear association 
between DCI and cerebral vessel narrowing in humans. However, 
it remains unclear whether the association between cerebral 
vessel narrowing and DCI is causative. Etminan et al. noted in 
their systematic review and meta-analysis (4,235 patients) that 
pharmaceutical interventions have decreased the incidence of 
radiographic vasospasm (decreased cerebral artery diameter on 
angiography or increased flow velocity on transcranial Doppler) 
without decreasing poor clinical outcomes (48). The authors note 
that methodological problems, inadequate sample sizes, insensi-
tivity of clinical outcome measures and mechanisms other than 
vasospasm that also contribute to poor outcomes could explain 
the dissociation between vasospasm and clinical outcome in their 
review. In contrast to these findings, Kimball et al. in a systematic 
review found that 24 of 27 publications (1,028 patients) reporting 
the use of transluminal balloon angioplasty noted an improve-
ment in vessel diameter and neurological deficits (49). This review 
also included mostly small, low-quality studies (based upon the 
GRADE classification system) (50).
The CONSCIOUS trials investigated the effect of the endothelin- 
receptor antagonist (ERA), Clazosentan, in the treatment of DCI 
after SAH (51, 52). Clazosentan was found to produce a dose- 
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dependent reduction in angiographic vasospasm but no significant 
effect on morbidity or mortality. Endothelin is involved in the 
regulation of a large variety of organ functions apart from its 
vasoconstrictor function. It may be that Clazosentan successfully 
reduced arterial narrowing but also inhibited endothelin’s organ 
regulatory functions masking any improvement due to improved 
cerebral diameter. Laban et al., in their systematic review of experi-
mental SAH studies of ERAs, demonstrated a 54% improvement 
in vessel diameter after administration but no significant effect on 
mortality and no studies reported effects on functional outcomes 
(53). The authors concluded that there was no neurobehavioral 
data to support progression from preclinical to clinical trials for 
ERAs. In contrast to ERAs, some of the experiments in this review 
did examine neurobehavioral scores. While there is not a large 
amount of data, there is a positive signal consistent with a substan-
tial effect. Similarly, a non-statistically significant improvement in 
outcome for the CGRP group was seen in the European CGRP 
in SAH trial (RR 0.88, CI 0.60–1.28). Johnston et al. did observe 
a statistically significant 88.9% treatment preference for CGRP 
versus placebo in their small study (38, 39). Therefore, although 
we do not think there is sufficient evidence to support progression 
directly to a Phase III trial we do think progression to a Phase I 
trial is appropriate.
Limitations of Studies
There were no female-only experiments and the majority of 
experiments in this systematic review used the single hemorrhage 
model of SAH (60%). The other forms were double injection 
and clot placement. Animals rarely develop a vessel narrowing-
related ischemic neurological deficit from any of these methods. 
Megyesi et  al. note that this is probably because animal brains 
have a plentiful collateral blood supply (54). While this is probably 
irrelevant for measuring the effect of αCGRP on vessel diameter, 
it becomes more problematic when trying to assess neurological 
outcomes. Another translational problem arises from the times 
of administration of αCGRP and assessment of neurobehavioral 
outcomes. In humans, DCI is said to occur most commonly 
between days 3 and 10 and cerebral vessel narrowing is maximal 
between days 6 and 10 after ictus (12). The experiments assessed 
in this review administered αCGRP before and up to 3 days after 
SAH and assessed the response within hours to one week after 
administration (Table  1). The authors also note that the best 
model of vasospasm seems to be the primate model in which a 
blood clot is placed around a large cerebral vessel (54). Only one 
of the studies we analyzed uses this model. More recently, Titova 
et  al. in their systematic review state that dog models of SAH 
are considered superior and that the ability of murine models to 
reflect human vasospasm is disputed (55).
One of the challenges of translating these animal data and 
methods to human trials is the invasive nature of the intrathecal 
route. Previous human trials with intravenous administration 
of αCGRP have used a continuous infusion owing to the short 
half-life of αCGPR in the systemic circulation (approximately 
7–10  min) (56). However, when administered into the cer-
ebrospinal fluid the effects of αCGRP have continued for 4–6 h 
(21, 26). Therefore, a continuous infusion of αCGRP into the 
cerebral spinal fluid may not be necessary. Furthermore, Toyoda 
et al. (37) and Sun et al. (32) demonstrate novel approaches to 
administering αCGRP, one via gene transfer and the other by 
intranasal delivery. If intraventricular administration of αCGRP 
in humans ameliorates cerebral vessel narrowing and avoids 
the adverse effects seen with intravenous delivery, both gene 
transfer and intranasal delivery offer potential alternatives with-
out the difficulties associated with an intraventricular drain.
CONCLUSiON
We demonstrate a significant dilation of cerebral arteries after 
αCGRP administration in animal models of SAH. However, there 
is insufficient animal data to determine the effect of αCGRP on 
neurobehavioral outcomes after SAH. We recommend that any 
future experimental studies investigating the effect of αCGRP 
in SAH include neurobehavioral scores as an outcome measure. 
The dilatory effect of αCGRP appears augmented after SAH, 
and there is some evidence that systemic effects of αCGRP are 
lessened by intrathecal administration compared with intrave-
nous administration.
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